Recombinant factor VIIa - rEVO Biologics/LFB

Drug Profile

Recombinant factor VIIa - rEVO Biologics/LFB


Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GTC Biotherapeutics; LFB Biotechnologies
  • Developer HEMA Biologics; LFB Biotechnologies; rEVO Biologics
  • Class Blood coagulation factors; Coagulants; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Haemophilia A; Haemophilia B

Most Recent Events

  • 06 Aug 2017 LFB completes the phase III PERSEPT3 trial in Haemophilia A & B (In infants, In children, In adults, In adolescents, In the elderly) in Ukraine, USA, Mexico, Russia, South Africa and Spain (Parenteral) (NCT02548143)
  • 09 Jan 2017 Preregistration for Haemophilia A and Haemophilia B (In adolescents, In adults, In children, In infants) in USA (Parenteral)
  • 09 Jan 2017 Efficacy and adverse events data from the phase III PERSEPT 1 trial in Hemophilia A and B released by LFB Biotechnologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top